Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.51 |
| ▸ | GRM1 | Q13255 | 8/20 | 0.51 |
| ▸ | CKS1B | P61024 | 2/20 | 0.48 |
| ▸ | SKP1 | P63208 | 2/20 | 0.48 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | WNT3A | P56704 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30899642 | 1.00 | GRM5 (0.51) | GRM5GRM1CKS1BSKP1SKP2 | |
| SCHEMBL30899634 | 0.88 | GRM1 (0.52) | GRM5GRM1GPR119LNPEPPDK4 | |
| SCHEMBL30366121 | 0.88 | GRM1 (0.52) | GRM5GRM1GPR119LNPEPPDK4 | |
| SCHEMBL30366420 | 0.82 | NAMPT (0.52) | GRM5GRM1GPR119LNPEPPDK4 | |
| SCHEMBL30913564 | 0.79 | GRM1 (0.56) | GRM5GRM1GPR119PDK4WNT3A | |
| SCHEMBL4006887 | 0.79 | GRM1 (0.56) | GRM5GRM1GPR119PDK4WNT3A | |
| SCHEMBL25200238 | 0.79 | GRM1 (0.49) | GRM5GRM1GPR119PDK4WNT3A | |
| SCHEMBL30899652 | 0.79 | GRM5 (0.44) | GRM5GRM1CKS1BSKP1SKP2 | |
| SCHEMBL30365846 | 0.79 | GRM5 (0.44) | GRM5GRM1CKS1BSKP1SKP2 | |
| SCHEMBL31198740 | 0.79 | GRM5 (0.52) | GRM5GRM1LNPEPMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360126-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2024-10-31 | — | — | US | disclosed |
| EP-4405051-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023046806-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360126-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | SSB, TPMT, KCNB2 | GRM5 2804/4885GRM1 1870/4885CKS1B 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.